Is Coeptis Therapeutics Holdings, Inc. (COEP) a Buy, Sell, or Hold?
Coeptis Therapeutics Holdings, Inc.
NASDAQ:COEP
$10.99 USD
-$1.03 (-8.57%)
- Volume
- 408.2K
- Average Volume
- 52.54K
- Market Capitalization
- $38.62M
- P/E Ratio
- -4.45
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $21.41
- Year Low
- $6.80
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.25
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | David Mehalick |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | COEP |
| CUSIP | 98878K108 |
| CIK | 0001759186 |
| Web | https://coeptistx.com |
| Phone | 724 934 6467 |
| Currency | USD |
| Employees | 6 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.02 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.25 |
| Quick Ratio | 3.25 |
| Cash Ratio | 2.87 |
Sales & Book Value
| Annual Sales | $1.36M |
| Price / Sales | 27.31 |
| Cash Flow | -1.33 |
| Price / Cash Flow | -4.83 |
| Price / Book | 3.18 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 1 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.81 |
| Trailing P/E Ratio | -4.45 |
| PEG Ratio | 0.02 |
| P/E Growth | 0.02 |
| Net Income | $-11.92M |
| Net Margin | -839.69% |
| Pretax Margin | -910.73% |
| Return on Equity | -83.85% |
| Return on Assets | -60.00% |
Financials Score
| AltmanZ Score | 0.75 |
| Piotroski Score | 4.00 |
| Working Capital | 4.09M |
| Total Assets | 19.79M |
| Ebit | -12.04M |
| Market Cap | 38.62M |
| Total Liabilities | 2.21M |
Poll Results
About Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Stock
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company’s product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for trea ... tment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson’s Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
2026-04-24 16:43:00
~ Shares to Commence Trading on the Nasdaq Global Market Under Ticker Symbol "ZSQR" Monday April 27, 2026 ~ FORT LAUDERDALE, Fla, April 24, 2026 /PRNewswire/ -- Z Squared, Inc. (Nasdaq: ZSQR) ("Z Squared" or the "Company"), a vertically integrated computing infrastructure company, today announced the completion of its business combination with Coeptis Therapeutics Holdings, Inc. ("Coeptis"). In connection with the business combination, the combined company has been renamed "Z Squared Inc." and its public shares are expected to commence trading on the Nasdaq Global Market under the ticker symbol "ZSQR" on Monday, April 27, 2026 (CUSIP: 98878K108).
Frequently Asked Questions
-
What is the current Coeptis Therapeutics Holdings, Inc. (COEP) stock price?
-
Coeptis Therapeutics Holdings, Inc.(NASDAQ:COEP) stock price is $10.99 in the last trading session. During the trading session, COEP stock reached the peak price of $21.41 while $6.8 was the lowest point it dropped to. The percentage change in COEP stock occurred in the recent session was --8.57% while the dollar amount for the price change in COEP stock was -$-1.03.
-
COEP's industry and sector of operation?
-
The NASDAQ listed COEP is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of COEP?
-
Daniel Alexander Yerace | Co-Founder, Vice President of Operations & Director
Christine Elise Sheehy | Co-Founder, VP of Compliance & Corporate Secretary
Brian Cogley | Chief Financial Officer
David Mehalick | Co-Founder, Chairman of the Board, Chief Executive Officer & President
| -
How many employees does COEP have?
-
Number of COEP employees currently stands at 6. COEP operates from 105 Bradford Rd, Wexford, PA 15090, US.
-
Link for COEP official website?
-
Official Website of COEP is: https://coeptistx.com
-
How do I contact COEP?
-
COEP could be contacted at phone #724 934 6467 and can also be accessed through its website. COEP operates from 105 Bradford Rd, Wexford, PA 15090, US.
-
How many shares of COEP are traded daily?
-
The average number of COEP shares traded daily for last 3 months was 52.54K.
-
What is the market cap of COEP currently?
-
The market value of COEP currently stands at $38.62M with its latest stock price at $10.99